Resource impact statement
No significant resource impact is anticipated
NICE has recommended pegcetacoplan, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor. It is recommended only if the company provides pegcetacoplan according to the commercial arrangement (see section 2 of guidance).
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option and the overall cost of treatment for this patient group is unlikely to change significantly with the introduction of pegcetacoplan.
Pegcetacoplan has a discount that is commercial in confidence. For enquiries about the patient access scheme contact mail.uk@sobi.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: